{"id":"budesonide-mmx","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Adrenal suppression (systemic corticosteroid effects)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is a glucocorticoid receptor agonist that suppresses local immune and inflammatory responses in the colon. The MMX (multi-matrix) delivery system uses pH-dependent and time-dependent release mechanisms to ensure the drug is released gradually throughout the entire colon, maximizing therapeutic effect while minimizing systemic absorption and associated side effects.","oneSentence":"Budesonide MMX is a corticosteroid formulated with multi-matrix technology to deliver the active drug throughout the colon for localized anti-inflammatory effects in inflammatory bowel disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:13.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction of remission)"},{"name":"Crohn's disease (colonic involvement)"}]},"trialDetails":[{"nctId":"NCT05915104","phase":"PHASE2","title":"Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-01-01","conditions":"Microscopic Colitis","enrollment":80},{"nctId":"NCT00801723","phase":"PHASE3","title":"(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-12","conditions":"Ulcerative Colitis","enrollment":123},{"nctId":"NCT00679380","phase":"PHASE3","title":"(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":514},{"nctId":"NCT00679432","phase":"PHASE3","title":"(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2008-06","conditions":"Ulcerative Colitis","enrollment":510},{"nctId":"NCT02586259","phase":"","title":"Effectiveness of Cortiment® in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-12","conditions":"Ulcerative Colitis","enrollment":378},{"nctId":"NCT04080713","phase":"PHASE1","title":"Cortiment® MMX Pharmacokinetic Study","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-09-16","conditions":"Healthy","enrollment":24},{"nctId":"NCT01532648","phase":"PHASE3","title":"Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-01-27","conditions":"Ulcerative Colitis","enrollment":510}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cortiment®","Budesonide Multi-Matrix System"],"phase":"phase_3","status":"active","brandName":"Budesonide MMX®","genericName":"Budesonide MMX®","companyName":"University of Calgary","companyId":"university-of-calgary","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide MMX is a corticosteroid formulated with multi-matrix technology to deliver the active drug throughout the colon for localized anti-inflammatory effects in inflammatory bowel disease. Used for Ulcerative colitis (induction of remission), Crohn's disease (colonic involvement).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}